CGRP RECEPTOR ANTAGONISTS
    9.
    发明专利

    公开(公告)号:NZ574097A

    公开(公告)日:2012-01-12

    申请号:NZ57409707

    申请日:2007-06-13

    Applicant: VERTEX PHARMA

    Abstract: Disclosed is a thiazolidine compound of formula (I) where the substituents are as disclosed in the specification. Example of compound of formula (I) include: 1-(1-(2-(4-Oxo-2-phenyl-3-((pyridin-4-yl)methyl)thiazolidin-5-yl)acetyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 3,4-Dihydro-3-(1-(2-(3-methyl-4-oxo-2-phenylthiazolidin-5-yl)acetyl)piperidin-4-yl)quinazolin-2(1H)-one and 3-(1-(2-(3-Isopentyl-4-oxo-2-phenylthiazolidin-5-yl)propanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one. Also disclosed is the pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula9I) in the manufacture of a medicament for treating or preventing headache; migraine; cluster headache; chronic tension type headache; pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; diabetes; non-insulin dependent diabetes mellitus; vascular disorders; inflammation; arthritis; bronchial hyperactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases; neurogenic cutaneous redness, skin rosaceous and erythema; tinnitus; inflammatory bowel disease, irritable bowel syndrome, or cystitis.

Patent Agency Ranking